<?xml version="1.0" encoding="UTF-8"?>
<p id="Par1239">
 <bold>Results:</bold> Patients whose preexisting antiplatelet therapy was continued showed increased mortality rates in contrast to patients whose medication was discontinued. The ICU mortality was significantly reduced from 41.6 % (37/89) to 20.4 % (23/113)(OR 0.36; 95 % CI 0.19 – 0.67; p = 0.0013). The hospital mortality was as well reduced from 51.7 % (46/89) to 25.7 % (29/113)(OR 0.32; 95 % CI 0.18 – 0.58; p &lt; 0.001). The mortality at 28 days was reduced from 46.1 % (41/89) to 20.7 % (23/111)(OR 0.31; 95 % CI 0.17 – 0.57; p &lt; 0.001). The remarkable high mortality at 90 days was reduced from 63.6 % (56/88) to 35.5 % (39/110)(OR 0.31; 95 % CI 0.18 – 0.56; p &lt; 0.001).
</p>
